Cepheid Reaffirms Financial Guidance in Wake of Swiss MRSA Study | GenomeWeb
NEW YORK (GenomeWeb News) – Cepheid today reaffirmed its previous 2008 financial guidance for revenues of between $182 million and $189 million and net income of between $3 million and $5 million, following a published study questioning the effectiveness of methicillin-resistant Staphylococcus aureus screening.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.